Intermountain Ventures was recently recognized by Silicon Valley Bank as being one of the “Most Active HealthTech Investors,” alongside leading investors and corporate venture capital groups from Google, Optum, Merck and Bayer—a notable accomplishment given Ventures’ short tenure.
Intermountain established Intermountain Ventures in 2019 as a wholly owned subsidiary to drive innovation, growth, and quality by seeking investments in leading emerging healthcare technology companies. Each year, based on discussions with Intermountain leadership, the Ventures team identifies key trends in healthcare, like the need for greater accessibility and reduced cost of care, to determine priority investment focus areas. At present, those focus areas include virtual first/hybrid care, health equity, value based care, data/bio, AI/automation and talent.
“Intermountain Ventures provides a unique advantage to Intermountain Healthcare,” says Clay Ashdown, senior vice president of Finance Operations. “The program can sort through massive amounts of noise in the marketplace, identify strategically-aligned nascent companies with true potential, and provide a forum to validate and enhance innovation to create clinical and economic value.”
The Ventures portfolio of transformative companies includes Omada, Axuall, Vivante, Transcarent, Vori Health, Unite US, Trusted, Culmination Bio, and others. These companies have introduced important innovations and corresponding clinical and quality benefits to both Intermountain and the broader healthcare ecosystem.
If you have questions regarding Intermountain Ventures and its activities, please send questions to ventures@imail.org with the subject line “Caregiver Questions.”